Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BIIB Biogen Inc

-6.99 (-3.10%)
May 23 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 992,271
Bid Price 218.10
Ask Price 228.43
News -
Day High 223.85


52 Week Range


Day Low 217.21
Company Name Stock Ticker Symbol Market Type
Biogen Inc BIIB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-6.99 -3.10% 218.22 20:00:00
Open Price Low Price High Price Close Price Prev Close
223.58 217.21 223.85 218.06 225.21
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
28,391 992,271 $ 218.79 $ 217,094,596 - 189.44 - 319.76
Last Trade Time Type Quantity Stock Price Currency
19:59:29 8 $ 226.63 USD

Biogen (BIIB) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Biogen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
31.7B 145.36M - 9.84B 1.16B 7.99 27.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Biogen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No BIIB Message Board. Create One! See More Posts on BIIB Message Board See More Message Board Posts

Historical BIIB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week231.60234.58217.21228.73925,545-13.38-5.78%
1 Month201.21236.90198.11220.391,152,98417.018.45%
3 Months221.76236.90189.44213.941,247,468-3.54-1.60%
6 Months231.25268.74189.44227.771,176,927-13.03-5.63%
1 Year305.23319.76189.44246.911,107,182-87.01-28.51%
3 Years285.60468.2499187.16264.771,238,833-67.38-23.59%
5 Years232.94468.2499187.16269.881,373,465-14.72-6.32%

Biogen Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Your Recent History

Delayed Upgrade Clock